Thermo Fisher Scientific to acquire Brammer Bio in $1.7 billion dealChristian Fernsby ▼ | March 25, 2019
Thermo Fisher Scientific and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash.
Acquisition Brammer Bio is on track to deliver $250 million of revenue
The business has nearly 600 employees at primary locations in Massachusetts and Florida.
Brammer Bio is on track to deliver $250 million of revenue in 2019 and expects to continue to exceed the projected market growth rate of 25 percent over the mid-term. Thermo Fisher expects the business to be accretive to adjusted earnings per share by $0.10 in the first full year of ownership. ■